ReviewMolecules (Basel, Switzerland)2024
Advances in Nano-Functional Materials in Targeted Thrombolytic Drug Delivery.
Review in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Berberine-Loaded Mesoporous Bioactive Glass Enhances Bone Repair through Combined Immunomodulatory and Osteogenic Effects.ACS omega · 2026Article
- Transforming stroke care: the promise of feedback-guided thrombolytic nanomedicine.Journal of nanobiotechnology · 2026Review
- Ultrasound-Mediated Thrombolysis: From Mechanistic Insights to Advanced Nanoplatforms and Clinical Translation.Advanced healthcare materials · 2026Review
- Nanozyme-Based Anti-Inflammatory Strategies in Cardiovascular Disease Management: Clinical Prospects and Challenges.International journal of nanomedicine · 2026Review
- Tissue Plasminogen Activator as an Approved Strategy for Ischemic Stroke: A Review of tPA's Structure, Mechanism of Action and the Novel Targeting Methods.Journal of molecular neuroscience : MN · 2025Review
- Targeting hemostatic enzymes: from mechanistic insights to therapeutic frontiers.Current opinion in hematology · 2025Review
- Nanomedicine in cardiovascular and cerebrovascular diseases: targeted nanozyme therapies and their clinical potential and current challenges.Journal of nanobiotechnology · 2025Review
- Systemic Impact of Platelet Activation in Abdominal Surgery: From Oxidative and Inflammatory Pathways to Postoperative Complications.International journal of molecular sciences · 2025Review
- Optimization and characterization of collagenase KU665299 and its application in effective in-vitro clot digestion.Biotechnology letters · 2025Article
- From micro to macro, nanotechnology demystifies acute pancreatitis: a new generation of treatment options emerges.Journal of nanobiotechnology · 2025Review
- Drug-loaded nanoparticles reduced platelet aggregation and blood coagulation.Frontiers in medical technology · 2025Article
- Stimuli-responsive Nano/Biomaterials for Smart Drug Delivery in Cardiovascular Diseases: Promises, Challenges and Outlooks.Current medicinal chemistry · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Thrombotic disease has been listed as the third most fatal vascular disease in the world. After decades of development, clinical thrombolytic drugs still cannot avoid the occurrence of adverse reactions such as bleeding. A number of studies have shown that the application of various nano-functional materials in thrombus-targeted drug delivery, combined with external stimuli, such as magnetic, near-infrared light, ultrasound, etc., enrich the drugs in the thrombus site and use the properties of nano-functional materials for collaborative thrombolysis, which can effectively reduce adverse reactions such as bleeding and improve thrombolysis efficiency. In this paper, the research progress of organic nanomaterials, inorganic nanomaterials, and biomimetic nanomaterials for drug delivery is briefly reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.